ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder. ResMed makes continuous positive ...
Investor's Business Daily on MSN1d
ResMed Tumbles As Organic Sales Growth Steps Down. Will These 'Mega Trends' Save It?ResMed stock was roughly flat late Thursday after the CPAP maker beat earnings expectations. Shares are in a buy zone.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results